New treatment approved by FDA for treating drug-resistant tuberculosis

FDA for treating drug-resistant tuberculosis

The US Food and Drug Administration (FDA) on August 14, 2019 approved pretomanid, it is one of the three latest drugs for new BPaL regimen. It has allegedly known to have helped in treating 90% of XDR tuberculosis with 5 pills a day, within a span of a mere six months during the Nix-TB trial in South Africa.

Tuberculosis is regarded as one of the leading infectious diseases in the world. According to reports, about 30,000 patients in the world are affected by XDR tuberculosis which does not respond to any of the four categories of antibiotics which are used presently.

The approval of BPaL regimen will thus help in curing several severe cases of tuberculosis patients. Based on the current therapy measures, XDR tuberculosis needs an intake of up to 40 pills every day for a minimum of 2 years. It has however known to cure only 34% of patients.

The three important drugs used in this case are bedaquiline, pretomanid, and linezolid. All of these three drugs are mycobactericidal, which also indicates that they help in killing tuberculosis bacilli. Based on reports of experts, other drugs work on two killers with one bacteriostatic drug. This hence helps in curbing the bacterial multiplication, but it continues to live in an inactive state.

Pretomanid has gained the latest approval, whereas the other two have known to be previously approved. Sources also suggest that some groups have argued to have a further testing of pretomanid before approving it.

Owing to the FDA approval, this will initiate a universal adoption by the World Health Organization (WHO) and other global health initiatives.